Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids.
Anabolic-androgenic steroids are synthetic derivatives of testosterone that some athletes have used to enhance muscle mass and improve their athletic performance. Ephedrine is a potent sympathomimetic agent that can lead to cardiomyopathy similar to that seen with catecholamine excess. Adverse cardiovascular events attributed to anabolic steroid and ephedra use, such as arrhythmias, myocardial infarction, cardiomyopathy, and sudden death, are rarely reported. Bodybuilders have used gamma-hydroxybutyrate, a potent secretagogue of growth hormone, to promote muscle development. Although dilated cardiomyopathy is a known complication of excess growth hormone levels, it has not been associated with use of gamma-hydroxybutyrate. A healthy 40-year-old man was admitted to our hospital for new-onset congestive heart failure and severe acute hepatitis that developed several months after he began using anabolic-androgenic steroids, ephedra, and gamma-hydroxybutyrate supplements. Analysis with an objective causality assessment scale revealed a probable adverse drug reaction between the patient's use of anabolic steroids, ephedra, and gamma-hydroxybutyrate and the development of his cardiomyopathy and acute liver injury.
Clark
Brychan M
BM
Department of Medicine, Wilford Hall USAF Medical Center, San Antonio, TX 78236, USA. brychan.clark@lackland.af.mil
Schofield
Richard S
RS
D000328:Adult; D045930:Anabolic Agents / Q000009:adverse effects*; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced*; D002492:Central Nervous System Depressants / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004357:Drug Synergism; D029790:Ephedra sinica / Q000009:adverse effects*; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D017114:Liver Failure, Acute / Q000139:chemically induced*; D008297:Male; D008696:Methandrostenolone / Q000009:adverse effects; D009277:Nandrolone / Q000009:adverse effects / Q000031:analogs & derivatives; D000077603:Nandrolone Decanoate; D012978:Sodium Oxybate / Q000009:adverse effects*; D013256:Steroids / Q000009:adverse effects*; D014891:Weight Lifting
D045930:Anabolic Agents; D002492:Central Nervous System Depressants; D013256:Steroids; D019382:Human Growth Hormone; D009277:Nandrolone; D012978:Sodium Oxybate; D008696:Methandrostenolone; D000077603:Nandrolone Decanoate